Capital Cell Review 2026

Startups · Spain · since 2014

Reviewed by Eugene Sokolovs, figures checked 2 Nov 2026

Spanish equity crowdfunding platform for biotech and health startups, running since 2015 and authorised by the CNMV: invest from €500, with every company reviewed by an independent expert network. €85 million invested directly in 149 companies.

Risk level
Highest
Crowdinform rating
Start from
€500
Money back in 24–60 months
Regulated
Yes
Licence details below
  • Can sell early
  • Mobile app

Returns and risk

How we set these levels

Risk level

Highest

Higher means more risk. 13 of 88 mature rounds are written off (about 9% of the money), there is no security of any kind, the only cash figure is from November 2022 beside an undated paper value, and investors in at least one company report being ignored after investing.

Return level

High

The platform values its portfolio at 2.7 times the money invested (October 2026), on paper, not money paid out. The last cash figure, from November 2022, was 0.51 euros back per euro invested.

Risk for the return

Medium

Set at editorial review. Startup shares are high risk and high return by nature: many fail, a few pay many times the money, and exits take years. Capital Cell is also the only platform we rate where an independent network of experts reviews every company before it is offered.

Money back in
24–60 monthsTypical loan or investment term

What the platform reports about losses (its own definitions)

Rounds written off
14.8%13 of the 88 funding rounds from April 2016 to September 2023 (12 companies) are labelled "write-off" (valued at zero) on the platform's track record, counted in August 2026. Calculated from the platform's own figures; counts rounds, not money.
Money in written-off rounds
9.03%€7.4 million invested by the crowd in rounds labelled "write-off", against about €82 million invested directly through the platform since 2016, counted in August 2026, calculated from the platform's own figures. Leaves out younger rounds and companies worth less than investors paid.

Capital at risk. Past returns do not predict future returns; a borrower can pay late or not at all.

Statistics

Last updated 2 Nov 2026

€85M
funded since 2014
149
projects funded
21,500
investors
4
projects open now on Crowdinform

Figures as the platform publishes them.

Pros and cons

Pros

  • Every company is reviewed by an independent network of more than 3,500 experts before it is offered, and a professional lead investor sets the price of each round.
  • Its public track record labels every past round as in business, exit or write-off, and it publishes audited accounts.
  • A specialist since 2015: €85 million invested directly in 149 health companies (October 2026), CNMV-authorised with a passport to 26 countries.
  • The portfolio is valued at 2.7 times the money invested on paper (October 2026), with exits including Vytrus's stock-market listing and GoodGut's sale to HIPRA (2021).

Cons

  • 13 of 88 mature rounds are written off, about €7.4 million of crowd money valued at zero (August 2026), and younger rounds have yet to age.
  • The only cash figure, 0.51 euros back per euro invested, dates from November 2022; the 2.7 times paper value is undated and undefined.
  • No maturity and no real market: you must find your own buyer, offer the company first and pay 8%; Bionure investors from 2017 are still waiting for a return.
  • In 2026 Bionure investors reported unanswered requests for a shareholders' meeting and turned to formal legal demands.
  • Nothing secures your money, and shares are usually held through a foundation whose board includes a Capital Cell appointee.

How it works

For investors

Minimum
€500
Fees
  • Investor fee: 8% of the transaction when you sell your certificates to another investor before an exit
Currencies
EUR
Languages
Swedish, English, French, Dutch, Spanish
Can sell early
Yes
Limits
Investors across the European Economic Area who pass the EU entry knowledge test and loss-bearing simulation. Non-experienced investors who put more than €1,000 or more than 5% of their net worth into one project must accept an explicit risk warning. Commitments can be withdrawn within 7 days.

For borrowers and companies

Fees
  • Fundraising fee: 8% of the total amount raised, on a successful round
  • Fundraising fee: EUR 1500 publication fee after a positive expert evaluation
Security
Nothing secures your money. You buy a stake in a young company, with no collateral, buyback, reserve fund, insurance or compensation scheme. Usually you do not hold the shares in your own name: a Dutch foundation (a STAK) owns them and issues you certificates that carry your economic and voting rights. The foundation is run by a board of three directors, one of them appointed by Capital Cell. Before a round completes, your money is held by an authorised financial institution, not by the platform or the company. The expert reviews check the science, the patents and the price of one round; they do not protect the value of your shares. Companies often raise more money later, which shrinks earlier investors' share.

About and licence

What it is

Capital Cell is an equity crowdfunding platform from Barcelona that invests only in young biotech, medical-device, diagnostics and digital-health companies. It has been running since 2015 and is run by PFP Capital Cell, S.L. Investors have put €85 million directly into 149 companies through it, and €168 million together with the professional investors who invest alongside them, across 175 funding rounds (October 2026). The site is available in seven languages.

How it works

You choose companies yourself, usually from €500 per round. Each company is first reviewed by the platform's independent network of more than 3,500 scientists, doctors, consultants and lawyers, then by an internal committee, with outside checks of its finances and patents. A professional lead investor, found by the company, sets the price and terms of each round, and the crowd invests alongside. The home page says only 3% of companies that approach the platform are selected; its FAQ says about one applicant in ten. Your money stays with an authorised financial institution until the round completes and is returned if the round fails. You can withdraw within 7 days of committing.

Returns

Capital Cell publishes no yearly return. Its home page shows a portfolio value of 2.7 times the money invested (October 2026), a value on paper based on later funding rounds, not money paid out; the page gives no date or method. It was 3.19 times in November 2022. Very little cash has come back: by November 2022 investors had received about 0.51 euros in cash for every euro invested, from four cash exits, and no newer cash figure has been published. The exits it names are Vytrus, which listed on the stock market, and GoodGut, sold to the drug company HIPRA in 2021; the amounts investors received are not published. Expect to wait: the platform speaks of three to six years, while investors in Bionure, funded in 2017, are still waiting for a return.

Losses and defaults

The platform labels every past round as "in business", "exit" or "write-off". Of the 88 rounds old enough to judge (April 2016 to September 2023), 13 rounds in 12 companies are written off and worth nothing. That is 14.8% of mature rounds, and €7.4 million, about 9% of the roughly €82 million invested directly by August 2026, calculated from the platform's own figures. The platform says 89% of its 149 companies are "in business" (undated, without saying how it counts exits). These figures will rise as younger rounds age, and they leave out companies that are still alive but worth less than investors paid. When a startup fails, shareholders are paid last and usually get nothing back.

What secures your money

Nothing secures your money. You buy a stake in a young company, with no collateral, buyback, reserve fund, insurance or compensation scheme. Usually you do not hold the shares in your own name: a Dutch foundation (a STAK) owns them and issues you certificates that carry your economic and voting rights. The foundation is run by a board of three directors, one of them appointed by Capital Cell. Before a round completes, your money is held by an authorised financial institution, not by the platform or the company. The expert reviews check the science, the patents and the price of one round; they do not protect the value of your shares. Companies often raise more money later, which shrinks earlier investors' share.

Who runs it and its licence

PFP Capital Cell, S.L. (Barcelona) is authorised by Spain's markets regulator, the CNMV, as a crowdfunding service provider under the EU crowdfunding regulation (register no. 12, effective 10 November 2023), and may serve investors in 26 other European countries. Its sole administrator is founder Daniel Oliver. It publishes audited accounts. In 2026 investors in one portfolio company, Bionure (now Accure Therapeutics), reported that their requests for a shareholders' meeting went unanswered and turned to formal legal demands.

Fees

The platform lists no fee for investing; card fees and legal costs are paid by the company raising money. Companies pay an 8% commission on the amount raised plus a €1,500 publication fee. If you sell your certificates to another investor before an exit, Capital Cell charges 8% of the transaction. Check each round's documents for any share of profit taken on a sale, which the platform's FAQ does not list.

Getting your money out

Usually you cannot sell when you want to. There is no maturity date and no repayment promise. Money comes back only if the company is sold, lists on a stock market or buys shares back. The platform runs a noticeboard where sellers can contact buyers, but you must find the buyer yourself, first offer the shares to the company and its founders, and pay 8%. The platform itself calls these investments medium term and without liquidity.

Our view

Return: High — the portfolio is valued at 2.7 times the money invested on paper (October 2026), though only about 0.51 euros per euro had come back as cash by November 2022. Risk: Very High (higher means more risk) — 13 of 88 mature rounds are written off, the cash figure is four years old beside an undated paper value, and some investors report being left without information. Risk-return: Medium — startup shares are high risk and high return by nature, and Capital Cell is the only platform we rate where an independent network of experts reviews every company before it is offered.

Licence

PFP Capital Cell, S.L. is authorised by the Spanish Comisión Nacional del Mercado de Valores (CNMV) as a crowdfunding service provider under Regulation (EU) 2020/1503, register no. 12, effective 10 November 2023, with a passport to 26 EEA countries. No deposit guarantee or investor compensation scheme covers investment losses.

Latest news and guides

Questions people ask

Is Capital Cell regulated?

Yes. PFP Capital Cell, S.L. is authorised by Spain's markets regulator, the CNMV, as a crowdfunding service provider under the EU crowdfunding rules (register no. 12, effective 10 November 2023), with a passport to 26 other European countries. Regulation does not protect you from losing money on a company.

Who holds my money and my shares?

Until a round completes, your money is held in escrow by an authorised financial institution, with payments processed by Marketpay (Pecunia Cards EDE). After that, the shares are usually owned by a Dutch foundation (STAK), which gives you certificates for your economic and voting rights; one of its three directors is appointed by Capital Cell.

What is the minimum investment?

Usually €500 per round, sometimes more. The platform suggests spreading about €10,000 over ten companies within a year.

What returns, and what losses so far?

No yearly return is published. The portfolio is valued at 2.7 times the money invested on paper (October 2026), but by November 2022 only about 0.51 euros per euro had come back in cash. 13 of the 88 rounds old enough to judge are written off, about €7.4 million of crowd money (August 2026).

What secures my investment?

Nothing. You own a stake in a young company, usually through a foundation, with no collateral, buyback, insurance or compensation scheme. If the company fails, you usually lose the whole amount. The expert reviews check each company before it is offered; they do not protect the value of your shares.

Can I sell my shares early?

Only if you find a buyer yourself through the platform's noticeboard, after offering the shares to the company and its founders first, and paying an 8% commission. Otherwise money comes back only from a sale of the company, a stock-market listing or a buyback, which can take many years.

What fees do I pay?

The platform lists no fee for investing; companies pay an 8% commission on the amount raised and a €1,500 publication fee. Selling your certificates to another investor before an exit costs 8% of the transaction. Check each round's documents for any share of profit taken on a sale.

What happens if Capital Cell or a company I backed fails?

If a company fails, shareholders are paid last and usually get nothing back. Your shares are held by a separate foundation, not by Capital Cell, so they are meant to stay yours if the platform fails, but no compensation scheme covers your losses.

How are companies chosen?

Every company is reviewed by the platform's independent network of more than 3,500 scientists, doctors, consultants and lawyers, then by an internal committee, with outside checks of finances and patents, and a professional lead investor sets the price. The home page says 3% of companies that approach it are selected; the FAQ says about one in ten applicants.

Ratings and reviews

Write a review
  • No reviews yet. Be the first to share how this platform worked for you.

Open projects on Capital Cell

Own a share AI 63 Medium Funded

Kairos Discovery

Capital Cell

Estimated return
up to 20×
platform's estimate
Valuation
€3,294,118

Raising €850k

From €1,000
See project
Own a share AI 73 High Funded

Aspivix

Capital Cell

Estimated return
4–7×
platform's estimate
Valuation
€26,318,642

Raising €675.5k

From €800
See project
Own a share AI 63 Medium Funding now

Airway Shield

Capital Cell

Estimated return
up to 8×
platform's estimate
Valuation
€8,000,000

Raising €800k

From €1,000
See project
Own a share AI 63 Medium Funded

Time is Brain

Capital Cell

Estimated return
up to 13×
platform's estimate
Valuation
€12,000,000

Raising €2.5m

From €1,000
See project

Alternatives to Capital Cell

SegoFinance

Property, Startups · earn interest / own a share

5.0

Regulated
Risk level
High
Risk-return
Very bad
Start from
€50

Adventurees

Startups, Business loans · earn interest / own a share

Not rated yet

Risk level
Low
Risk-return
Bad
Start from
€1,000

Support Crowdinform

Your contribution pays for the research and keeps the reviews free for everyone. Choose what works for you.

One timeA single contribution MonthlyOngoing support, cancel any time

Secure payment by Stripe.

Sign in to get alerts

Free. You can stop alerts at any time.

Join as an expert

Tell us about your experience. We read every message and reply by email.

We keep only what you send here, to answer you. Privacy

Report a mistake

Tell us what is wrong. We check it against the platform's own information and fix the page.

We keep only what you send here, to answer you. Privacy

Sign in

Unlock full AI reviews, ask the project chat and write reviews.

Forgot password?

or

Continue with Google

New here? Create a free account

Create a free account

You get 15 full AI reviews and 15 AI questions free.

0 of 14 characters

At least 8 characters, not only numbers, not a common password.

or

Continue with Google

By creating an account you agree to the Terms of use and the Privacy policy.
Terms · Privacy

Already have an account?

Forgot your password?

Enter your email and we'll send a link to set a new one.